CN1160463C

CN1160463C - Human papillomavirus E6/E7 fusion gene and its efficient expression carrier and fusion protein vaccine

Info

Publication number: CN1160463C
Application number: CNB021171432A
Authority: CN
Inventors: 赵清正
Original assignee: Cancer Hospital and Institute of CAMS and PUMC
Current assignee: Cancer Hospital and Institute of CAMS and PUMC
Priority date: 2002-04-24
Filing date: 2002-04-24
Publication date: 2004-08-04
Anticipated expiration: 2022-04-24
Also published as: CN1381583A

Abstract

The present invention relates to a human papillomavirus E6/E7 fusion gene, a preparation method of the gene, the construction and an expression carrier of a high-efficient expression carrier containing the gene, a fusion protein obtained by the gene, and the application of the fusion gene and the expression protein to medical science and the preparation of medicine (vaccines) for treating tumors such as cervical carcinoma, etc. The expression level of the fusion gene of the present invention accounts for about 40 % the total proteins of bacteria, and is about 15 times higher than that reported overseas. Moreover, the present invention has the advantages of safety, effectiveness and easy mass production.

Description

Human papillomavirus E6/E7 fusion gene and efficient expression vector thereof and amalgamation protein vaccine

Invention field

The present invention relates to a kind of human papillomavirus E6/E7 fusion gene, the preparation method of this gene, the structure and the expression vector that contain the efficient expression vector of this gene, the fusion rotein that utilizes this gene to obtain, and described fusion gene and expressing protein are in medical science and the application in the medicine of tumours such as preparation treatment cervical cancer.

Technical background

Cervical cancer is one of modal major malignant tumor of women, is No. second killer who causes the female tumor death.At present, methods of treatment is still based on operation and radiotherapy.Though certain progress has been arranged aspect treatment, survival rate was still paced up and down about 50% in 5 years.There is 40% patient dead because of recurring, shifting eventually approximately.Therefore, the new treatment measure of research and develop new control and be still one of important topic that various countries oncology worker pays close attention to biological products.

Massive epidemiology and clinical study both at home and abroad is verified, HPV16 be the main diseases viral disease that causes woman uterus cancer because of, have approximately in China due to 66% cervical cancer patient infects by HPV16, all the other are HPV18, due to 33 and 58 types.Route of infection is mainly transverse horizontal and propagates (being that a plurality of sexuals propagate mutually) and two kinds of approach of mother and baby's vertical transmission (Chinese tumour magazine, 14:2932-296,1992), with the 60%-78% basically identical (Int.J.Cancer of state's reports such as Russia and Japan, 85:313-318,2000; JPN, J, Cancer Res, 86:28-34,1995).

Along with developing rapidly and deeply of molecular biology research.Mechanism of carcinogenesis to HPV virus has had more definite understanding.Usually behind the HPV virus infection host cell, its DNA is incorporated in the genome of cell, but later most gene such as glutelin L1 and L2 and early stage albumen E1, E2, E4, E5 is deleted and lose from host DNA.Two oncogenes of E6 and E7 still are incorporated in the genome.Research work is verified, and the continuous expression of these two genes is essential (HPV and Cervical Cancer.Oxford UniversityPress, 1994, London for canceration and the malignant phenotype that keeps tumour; Intl.J.Gynecol.Pathol.19:16-28,2000; EMBO J, 8:513-519,1989).Therefore, these two genes become the focus that people study canceration mechanism and control usefulness new biological product gradually.

The investigator has once carried out more research to glutelin L1 and has observed.Though this protein vaccine has certain prophylactic effect to the infection of HPV virus, the infected then there are not prevention and therapeutic action (Int.J.Cancer 81:881-888.1999; J Natl Cancer Inst 93:284-292,2001).The technical barrier that has most critical in the preparation process is to use VLP (virus-like particle).Be that product must be through the suitable VLP (J.Natl.Cancer Inst.93:284-292,2001) of secondary to three time super centrifugal acquisition configuration.And supercentrifugal plant and instrument costliness, and treatable sample size is few; Need cell cultures with insect expression system, need inoculation one by one with the roller culturing bottle, consuming time, consumption material, trivial operations, easily pollution and expression amount are lower.L1 albumen with procaryotic cell expression, though expression level is higher, behind column chromatography, the VLP yield that the configuration that obtains through super centrifugal method is suitable is too low again, only be last super when centrifugal Tot Prot 2/10000ths to 5/10000ths (Virology, 243:423-431.1998).

For above-mentioned reasons, a lot of difficulties have been brought to the mass-producing batch process.

In recent years, abroad begin E6 and E7 gene as main direction.Experimentation on animals shows, uses the E7 albumen of expressing with prokaryotic system that prevention effect is arranged separately, use separately E6 albumen also have effect about 55% (Cancer Res, 58:724.1998).There are some researches prove, obviously be better than using separately wherein a kind of (CancerRes.59:1184-1187,1999) with E6 and two kinds of proteic effects of E7 simultaneously.Therefore, the investigator once imagined use E6/E7 fusion rotein as vaccine in the hope of further improving prevention effect.But there is not using value owing to the expressing fusion protein level of E6 gene itself or E6/E7 is too low.The external report fusion rotein of prokaryotic expression wild-type E6/E7, after IPTG induces, expression level only is 2.5% (CancerRes.59:1184-1187.1999) of bacterial protein, and owing to is that its security is subjected to people's query without the wild-type oncoprotein of transforming.The virus vaccines that contains E6 and E7 gene, or be the dna vaccination of carrier with the plasmid, owing to may be incorporated in the cellular genome, also there is safety issue.With synthetic polypeptide vaccine, cost is high and also need do the HLA evaluation earlier, and use range is restricted.

Summary of the invention

The contriver is through discovering in a large number, after the E7 gene fusion with the nucleotide sequence of 1-120 amino acids before the coding of the E6 gene of HPV and HPV, makes us having obtained efficiently expressing of gene unexpectedly.

Therefore, an object of the present invention is to provide human papillomavirus E6/E7 fusion gene, this fusion gene comprises the amino acid whose nucleotide sequence (comprising B-epi-position (1-23aa) complete among the E6 and CTL-epi-position (29-38aa)) of its 1-120 position of coding of the E6 gene of HPV at least, and among the E7 complete most critical and be proved to be 2 CTL-epi-position (11-20aa that truly have tumor-suppression activity; 49-57aa) and Th-epi-position (48-54aa) and 3 B-epi-position (1-18aa; 25-37aa; 43-60aa), be that the nucleotide sequence of 1-60 amino acids (also can comprise the preceding amino acid whose nucleotide sequence more than 60 of coding before the coding at least among the E7, preceding 70 the amino acid whose nucleotide sequences of for example encoding are until coding 98 amino acid whose nucleotide sequences altogether).

The leucic codon of the 50th of the coding of E6 gene wherein, the codon of the halfcystine that the E7 genes encoding is the 24th and the 26th 's L-glutamic acid can adopt the rite-directed mutagenesis method to carry out transgenation, makes its forfeiture cause the ability of cancer suppressor gene inactivation.

The characteristics of this gene are to efficiently express the E6/E7 fusion rotein in the host.

This fusion gene prepares by following steps:

(A) obtain E6, E7 gene;

(B) with the leucic codon of the 50th of the coding of E6 gene, the codon of the halfcystine that the E7 genes encoding is the 24th and the 26th 's L-glutamic acid carries out rite-directed mutagenesis;

(C) nucleotide sequence of the coding 1-120 amino acids of the E6 gene behind the above rite-directed mutagenesis and the nucleotide sequence of the E7 gene behind the rite-directed mutagenesis are merged.

Another object of the present invention provides the structure and the described efficient expression vector of the efficient expression vector of above-mentioned fusion gene, comprise with described fusion gene and make recombinant plasmid, again with recombinant plasmid transformed to the host.

Another purpose of the present invention provides the protein vaccine that utilizes above-mentioned fusion gene to obtain.

A further object of the invention provides above-mentioned fusion gene and the application of fusion rotein in medical science.

Further object of the present invention provides the application in above-mentioned fusion rotein treats and/or prevents cancers such as cervical cancer in preparation the medicine.

Human papillomavirus E6/E7 fusion gene of the present invention can be used for preparing the protein vaccine that is used to prevent and treat cervical cancer safe, effective and that efficiently express.For the control of cervical cancer provides new biotechnology preparation.Gene is transformed its expression level of back through sudden change and other and accounted for about 40% of total bacterial protein, and is 2.5% higher about 15 times than what abroad reported, and safety, effectively, and easily production in enormous quantities.

Do not see similar report by retrieval both at home and abroad as yet.

Description of drawings

Fig. 1: the SDS-polyacrylamide gel electrophoresis is analyzed the expression level of (10%) target protein in different time points.M, protein standard molecular weight Marker; 1, inductive engineering bacteria not; 2-6 is respectively with IPTG and induced 1 hour, and 2 hours, 3 hours, target protein expression level after 4 hours and 5 hours.

Fig. 2: protein vaccine is to the protective effect on cancer risk (experimental technique is seen text in detail) 1 of laboratory animal, protein vaccine+IFA adjuvant group; 2, IFA adjuvant group; 3, the physiological saline group

Fig. 3: protein vaccine is to the restraining effect (experimental technique is seen text in detail) 1 of tumor growth, protein vaccine+IFA adjuvant group; 2, IFA adjuvant group; 3, the physiological saline group

Embodiment 1

One, the transformation of HPV16 virus E6 and E7 gene and fusion gene is synthetic:

1, E6, E7 gene obtains

From cervical cancer patient tumors tissue, extract genomic dna with ordinary method, amplify E6 and E7 gene respectively with PCR method again.Through sequential analysis, the E7 gene DNA sequence is consistent with external report, 98 amino acid of encoding altogether; And the E6 gene DNA sequence is except T → C of the 259th, all the other and external report consistent 158 amino acid of encoding altogether (Virology, 145:181-185,1985).The sudden change of this point causes amino acids coding to become arginine (the 87th amino acids in the E6 albumen) by halfcystine.Because this catastrophe point is positioned at outside E6 protein B-epi-position and the CTL-epi-position, so its immunogenicity is not had influence (as follows).

2, the rite-directed mutagenesis of E6 and E7 gene

Because the 50th leucine (Leu) is the critical sites that causes cancer suppressor gene P53 inactivation in the albumen of E6 coded by said gene, by rite-directed mutagenesis it is changed into glycine (Gly).Again owing to the 24th halfcystine (Cys) and the 26th L-glutamic acid (Glu) in the E7 albumen are the critical sites that causes the study of tumor suppressor genes Rb inactivation.All adopt the method for rite-directed mutagenesis that it is changed into glycine (Gly) in these two amino acid.E6 after the sudden change and E7 gene be called after mE6 and mE7 respectively.

3, mE6 _ΔME7 _ΔSynthesizing of fusion gene:

Be template with increase amino acid whose encoding sequence totally 360 base pairs of its 1-120 position of PCR method at first, and add the EcoR1 site at its 5 ' end with above-mentioned mE6.Divide the elongated segment method at mE6 with PCR then _Δ3 ' end progressively add preceding 60 amino acid (1-60 amino acids) of mE7.And 3 ' end adds the Not1 site.The fusion gene sequence that is obtained through the sequential analysis proof is correct, has kept the site of sudden change.Called after HPV16-mE6 _Δ/ mE7 _Δ(seeing SEQ ID No.1).The fusion gene of Gou Jianing has kept B-epi-position (1-23aa) and CTL-epi-position (29-38aa) (Clin, Exp.Immunol, 115:397-403,1999 complete among the E6 thus; J.Immunol.154:5934-5939.1995) and among the E7 complete most critical and be proved to be 2 CTL-epi-position (11-20aa that truly have tumor-suppression activity; 49-57aa) and Th-epi-position (48-54aa) and 3 B-epi-position (1-18aa; 25-37aa; 43-60aa) (J, Immunol, 154:5934-5943,1995; Eur.J.Cancer, 35:946,1999; J.Immunother, 21:399.1998; Virology, 231:155-166,1997).

Two, the evaluation of the structure of efficient expression engineering and product

HPV16-mE6 with above-mentioned acquisition _Δ/ mE7 _ΔAfter the fusion gene fragment is cut with EcoRI and Notl enzyme, directed cloning (Novagen company) transformed into escherichia coli DH5a in PET30a (+) carrier again, containing on the LB-plate of 50ug/ml kantlex, 37 ℃ of overnight incubation, the picking positive colony, extract recombinant plasmid with ordinary method, cut evaluation through enzyme.To contain goal gene recombinant plasmid transformed e. coli bl21 (DE3) again (Novagen).Containing on the LB-plate of 50ug/ml kantlex, in 37 ℃ of overnight incubation.80 single bacterium colonies of random choose are observed expression.Expression condition is: with fresh LB nutrient solution (containing the 50ug/ml kantlex).Picking list bacterium colony is inoculated in gnotobasis in the 5ml nutrient solution test tube of (containing the 50ug/mL kantlex), 37 ℃ of overnight incubation on shaking table.Next day, the ratio in 1: 50 was inoculated in the 20ml nutrient solution, and 37 ℃ are shaken training about 3-4 hour, when O.D.600 to be grown to is 0.5-0.7, added 1mM (final concentration) IPTG and induced 3-5 hour.Get 1ml bacterium liquid then in 4 ℃, 4000 rev/mins, centrifugal 5 minutes, abandon supernatant adding routine and split bright liquid with albumen, after the ultrasonication, carry out SDS-PAGE electrophoresis (10%) according to a conventional method.After electrophoresis finishes,, with after the destainer decolouring, can obviously see the protein band of a treaty 30KD again with Coomassie brilliant blue staining fluid dyeing 2 hours.This protein band does not almost see Chu in not adding the control tube of inductor.Through carrying out Western blot Analysis and Identification respectively, prove that this albumen is the fusion rotein of E6 and E7, and molecular weight fulfills the expectation with anti-HPV16E6 and E7 (SantaCruz company product).Ferment with similarity condition, the sample of getting different time points (1 to 5 hour) is through the SDS-PAGE electrophoretic analysis again, and the BSA with concentration known is that reference standard carries out electrophoresis simultaneously simultaneously.After the dyed and decolouring, carry out optical density(OD) calculating with automatic imaging scanner.When fermented incubation time is 5 hours, the target protein product is about 40% of a bacterial protein.Than the total length wild-type E6/E7 fusion protein product expression level of external report account for bacterial protein 2.5% high about 15 times (Cancer Research, 59:184-1187.1999).The electrophoresis result of different time sampling after product expression level is seen Fig. 1.Because cloning site is EcoR1 and Not1, this expression product has His-Tag and S-Tag at 5 ' end.The HPV6b-L2E7 recombinant vaccine of producing with similar approach is used for the treatment of pointed condyloma and has obtained effect preferably, by the second stage of clinical observation (J.Infect.Deseases 1999:179:612-618).

Three, the purifying of protein product (bacterium of cultivating with 100ml is an example)

1, harvested cell; Treat cell (containing above-mentioned recombinant plasmid) 37 ℃ of shaking table incubation growth when OD600 is 0.5-0.7, adding the IPTG ultimate density is 1mM.Continue to cultivate 3-4 hour 4000g, 4 ℃ of centrifugal 10 minutes collection intestinal bacteria again.Inhale as much as possible and abandon supernatant.Then with cell suspension in the 4ml solution I, (500mM NaCl, 20mM Tris-HCl, PH8.0).Suspend in the even rearmounted ice-water bath ultrasonication cell (each ultrasonic 3 seconds, stopped totally 30 times 3 seconds).

2, the collection of inclusion body; Because expressing protein is in inclusion body, with above-mentioned sample through supersound process in 16000g, 4 ℃, centrifugal 15 minutes.Abandon most supernatant, collecting precipitation as far as possible.To precipitate resuspending in solution I, repeated centrifugation once, further to remove foreigh protein removing.

3, the precipitation with above-mentioned collection is an inclusion body.Be suspended in 5mL and contain in the solution I of 8M urea element, mix, put in the ice-water bath 1 hour with the dissolving inclusion body.Then in 16000g, 4 ℃ centrifugal 20 minutes, keep supernatant, discard insoluble material.And filter with the strainer of 0.45um.Getting the step purifying ready uses.

4, (10cm * 0.6cm) includes 2.5ml chromatography media TALON to install chromatography column in advance ^TMMetal affinity chromatography resin (Clontech company), and used solution I (containing 8M urea element) balance good standby.Above-mentioned filtering solution is carefully added in the post along tube wall, do not make the resin levitating.The control flow velocity about 25ml/ hour (be equivalent to column volume 10 times/hour), promptly about 0.5ml/ branch.

5, with 25ml solution I (containing 8M urea element) flushing pillar, flow velocity is the same, to remove impurity albumen.

6, with the 15ml solution II (the 20mM imidazoles, 500mM NaCl, 8M urea element, 20mMTris-HCl pH8.0) washes post further to remove the foreign protein of non-specific binding.Flow velocity is the same.

7, wash-out and collect albumen; With 10mL solution III (400mM imidazoles, 500mM NaCl, 8M urea element, 20m M tris-HCl, PH8.0) wash-out target protein.Flow rate control is at the 0.3ml/ branch, and substep is collected, every pipe 0.3ml.

8, walk the SDS-PAGE electrophoresis, collect situation to check target protein.Merge contain target protein respectively manage sample.

9, (the physiological saline wash-out is used in 1 * 35cm) desalination, and substep is collected with sephadex G50 gel-filtration.Flow velocity 0.5ml/ branch, the 1ml/ pipe.Protein content in each pipe of electrophoretic examinations, and use the BSA leakage of electricity arteries and veins of concentration known simultaneously, to estimate content.Merge each pipe that contains target protein, with spectrophotometry protein content (Lowry method).

In order to last method: through revision test, the target protein rate of recovery is substantially at 50-60%.With 1 liter of fermented liquid, amplify above steps in proportion, finally can get product (purity is about 95%), 150 to 180mg.

Four, make laboratory animal repel attack---the protective effect on cancer risk of cancer cells after the amalgamation protein vaccine immunity

With C57B1/6 mouse (about 8 weeks) is laboratory animal.Behind the vaccine immunity animal, (derive from the tumour cell of mouse, for using HPV16 type E6 and E7 gene with the TC-1 tumour cell, reach activated Ras oncogene and be transformed, referring to Cancer Res, 56:21,1996, be so kind as to give by doctor Wu of U.S. Johns Hopkins university).The inoculation animal is observed tumour and takes place and growing state.Concrete experimental program is as follows: 30 of laboratory animal are divided three groups at random, 10 every group.First group, every animal subcutaneous injection contains incomplete freund adjuvant (IFA) 100uL of 15ug protein vaccine; Second group of every animal only injected the IFA with volume; The 3rd group, every animal subcutaneous injection is with the physiological saline of volume.Back 10 days of immunity for the first time, again immunity once, dosage is the same.Every animal right abdomen subcutaneous vaccination 1 * 10 is given in back 10 days of immunity for the second time ⁵The TC-1 tumour cell.Observe the tumor growth situation weekly twice, measure gross tumor volume.With V=a ²B/2 calculates gross tumor volume, wherein; V is a gross tumor volume, and a is a minor axis, and b is the tumour major diameter.Behind the inoculated tumour cell 60 days, first group (vaccine group) do not see tumor growth: second group (IFA group) and the 3rd group of (physiological saline group) all animals all have tumor growth, and tumor average volume is respectively 465 ± 25 cubic millimeters and 470 ± 35 cubic millimeters (Fig. 2).After showing vaccinate, effectively prophylaxis of tumours growth.

Research work is verified, behind the carcinogenic HPV virus infection host, its E6 and E7 gene are incorporated in the host cell gene group always and express, through long process, make host cell generation hyperplasia gradually, gradually develop into cancer cells again, be called carcinoma in situ, and then also invade profit towards periphery and grow up to tumour through division growth.Therefore, experimental results show that originally this protein vaccine can block the formation of tumour, and have prophylactic effect.Can be used for HPV16 the infected high risk population's anti-cancer work.

Five, amalgamation protein vaccine is to the restraining effect of growth of tumour cell---treatment, prevention of postoperative relapse and metastasis

Laboratory animal, tumour cell is the same.Experimental program is as follows: totally 33 of laboratory animal, every animal subcutaneous vaccination 1 * 10 ⁵The TC-1 tumour cell.After 20 days, check the tumor growth situation, have 30 animals that the tangible little tumour that arrives (about 5-8 cubic millimeter) is all arranged through observation.Wherein there are three to can not determine and discard.It is divided into three groups at random, 10 every group; First group (treatment group); Subcutaneous injection contains the IFA100uL of 15ug protein vaccine; Second group (IFA group), every animal injection 100ul IFA adjuvant; The 3rd group (physiological saline group), every animal subcutaneous injection 100ul physiological saline.Inject once by above-mentioned dosage again behind the 10d.Observe to 60 days (from inoculated tumour cytometer evaluation time), secondary is observed the tumor growth situation weekly always.During to experimental observation to 60 day, first group (treatment group) only two animal tumors has growth, and is significantly less than other group; Second group and the 3rd group of tumour are all grown, and average-volume is respectively 10 ± 3mm ³, 650 ± 35mm ³, 680 ± 45mm ³(Fig. 3).

As previously mentioned, there is 40% cervical cancer patient finally to cause death approximately because of relapse and metastasis.Its reason mainly is because through behind operation and/or the radiotherapy, still remaining in the body have a cancer cells, these cancer cells are not many or relatively disperse to form the knurl piece that as seen maybe can touch and fail excision owing to quantity, also are difficult for finding due to (being called " subclinical focus ") with other inspection means such as CT or the diagnosis of X-photo-beat sheet.Originally experiment showed, with amalgamation protein vaccine and can significantly suppress growth of tumour cell, illustrate that the prepared new fusion protein vaccine of the present invention has better action aspect treatment and the prevention transfer and relapse.

To sum up, advantage of the present invention is to be stranded and to have guaranteed its security by transforming HPV16E6 and E7 base, and has realized efficiently expressing, and has improved nearly 15 times (CancerRes 95:1184,1999) than the wild-type of external report.The purified back of product mixes with freund 's incomplete adjuvant after (this adjuvant be used for clinical for many years) be prepared into vaccine, has protective effect on cancer risk and treatment function through the experimentation on animals proof.Prevent cervical cancer to reach cervical cancer patient postoperative prevention of recurrence for the high risk population who infects HPV16 virus, transfer has important use undoubtedly and is worth.

Embodiment 2

According to carrying out with step 1 and the similar method of step 2 of embodiment 1, just obtain E6 and E7 gene from the HPV33 C-type virus C, obtained the fusion gene and the carrier of high expression level equally.

Embodiment 3

According to carrying out with step 1 and the similar method of step 2 of embodiment 1, just obtain E6 and E7 gene from the HPV18 C-type virus C, obtained the fusion gene and the carrier of high expression level equally.

Embodiment 4

According to carrying out with step 1 and the similar method of step 2 of embodiment 1, just obtain E6 and E7 gene from the HPV58 C-type virus C, obtained the fusion gene and the carrier of high expression level equally.

Sequence table

SEQ?ID?No.1

(a) sequence signature

Length: 540 base pairs

Type: nucleic acid

Chain: two strands

Topological framework: linearity

(b) sequence description

9 18 27

5’ATG CAC CAA AAG AGA ACT GCA ATG TTT

Met His Gln Lys Arg Thr Ala Met Phe

36 45 54

CAG GCA CCA CAG GAG CGA CCC AGA AAG

Gln Ala Pro Gln Glu Arg Pro Arg Lys

63 72 81

TTA CCA CAG TTA TGC ACA GAG CTG CAA

Leu Pro Gln Leu Cys Thr Glu Leu Gln

90 99 108

ACA ACT ATA CAT GAT ATA ATA TTA GAA

Thr Thr Ile His Asp Ile Ile Leu Glu

117 126 135

TGT GTG TAC TGC AAG CAA CAG TTA CTG

Cys Val Tyr Cys Lys Gln Gln Leu Leu

144 153 162

CGA CGT GAG GTA GGT GCA TTT GCT TTT

Arg Arg Glu Val Gly Ala Phe Ala Phe

171 180 189

CGG GAT TTA TGC ATA GTA TAT AGA GAT

Arg Asp Leu Cys Ile Val Tyr Arg Asp

198 207 216

GGG AAT CCA TAR GCT GTA TGT GAT AAA

Gly Asn Pro Tyr Ala Val Cys Asp Lys

225 234 243

TGT TTA AAG TTT TAT TCT AAA?ATT AGT

Cys Leu Lys Phe Tyr Ser?Lys Ile Ser

252 261 270

GAG TAT AGA CAT TAT CGT TAT AGT TTG

Glu Tyr Arg His Tyr Arg Tyr Ser Leu

279 288 297

TAT GGA ACA ACA TTA GAA CAG CAA TAC

Tyr Gly Thr Thr Leu Glu Gln Gln Tyr

306 315 324

AAC AAA CCG TTG TGT GAT TTG TTA ATT

Asn Lys Pro Leu Cys Asp Leu Leu Ile

333 342 351

AGG TGT ATT AAC TGT CAA AAG CCA CTG

Arg Cys Ile Asn Cys Gln Lys Pro Leu

360 369 378

TGT CCT GAA ATG CAT GGA GAT ACA CCT

Cys Pro Glu Met His Gly Asp Thr Pro

387 396 405

ACA TTG CAT GAA TAT ATG TTA GAT TTG

Thr Leu His Glu Tyr Met Leu Asp Leu

414 423 432

CAA CCA GAG ACA ACT GAT CTC?TAC GGT

Gln Pro Glu Thr Thr Asp Leu Tyr Gly

441 450 459

TAT GGT CAA TTA AAT GAC AGC TCA GAG

Tyr Gly Gln Leu Asn Asp Ser Ser Glu

468 477 486

GAG GAG GAT GAA ATA GAT GGT CCA GCT

Glu Glu Asp Glu Ile Asp Gly Pro Ala

495 504 513

GGA CAA GCA GAA CCG GAC AGA GCC CAT

Gly Gln Ala Glu Pro Asp Arg Ala His

522 531 540

TAC AAT ATT GTA ACC TTT TGT TGC AAG

Tyr Asn Ile Val Thr Phe Cys Cys Lys

TAA?3’

SEQ?ID?No.2

(a) sequence signature

Length: 180 amino acid

Type: albumen

Chain: strand

Topological framework: linearity

(b) sequence description

Met His Gln Lys Arg Thr Ala Met Phe

5

Gln Ala Pro Gln Glu Arg Pro Arg Lys

10 15

Leu Pro Gln Leu Cys Thr Glu Leu Gln

20 25

Thr Thr Ile His Asp Ile Ile Leu Glu

30 35

Cys Val Tyr Cys Lys Gln Gln Leu Leu

40 45

Arg Arg Glu Val Gly Ala Phe Ala Phe

50

Arg Asp Leu Cys Ile Val Tyr Arg Asp

55 60

Gly Asn Pro Tyr Ala Val Cys Asp Lys

65 70

Cys Leu Lys Phe Tyr Ser Lys Ile Ser

75 80

Glu Tyr Arg His Tyr Arg Tyr Ser Leu

85 90

Tyr Gly Thr Thr Leu Glu Gln Gln Tyr

95

Asn Lys Pro Leu Cys Asp Leu Leu Ile

100 105

Arg Cys Ile Asn Cys Gln Lys Pro Leu

110 115

Cys Pro Glu Met His Gly Asp Thr Pro

120 125

Thr Leu His Glu Tyr Met Leu Asp Leu

130 135

Gln Pro Glu Thr Thr Asp Leu Tyr Gly

140

Tyr Gly Gln Leu Asn Asp Ser Ser Glu

145 150

Glu Glu Asp Glu Ile Asp Gly Pro Ala

155 160

Gly Gln Ala Glu Pro Asp Arg Ala His

165 170

Tyr Asn Ile Val Thr Phe Cys Cys Lys

175 180

Claims

1, the E6/E7 fusion gene of human papillomavirus, it is characterized in that this fusion gene comprises the amino acid whose nucleotide sequence of its 1-120 position of coding of the E6 gene of HPV16,1-60 amino acids or whole amino acid whose nucleotide sequence before the coding at least in the E7 gene of HPV16, wherein with the codon mutation of the Methionin of the 50th of the coding of E6 gene codon, the codon of the halfcystine of the 24th of E7 genes encoding and the 26th 's L-glutamic acid is sported the codon of coding glycine respectively for the coding glycine.

2, according to the E6/E7 fusion gene of claim 1, be characterised in that the E6 gene has the nucleotide sequence of the 1-360 position of SEQ ID No.1, the E7 gene has the nucleotide sequence of the 361-540 position of SEQ ID No.1.

3, the efficient expression vector that contains each fusion gene among the claim 1-2.

4, by fusion rotein according to each fusion gene coding among the claim 1-2.

5,, be characterised in that it has the aminoacid sequence of SEQ ID No.2 according to the fusion rotein of claim 4.

6, treat and/or prevent the medicine of HPV relative disease or the application in the vaccine according to each fusion gene among the claim 1-2 in preparation.

7, treat and/or prevent the medicine of cervical cancer or the application in the vaccine according to each fusion gene among the claim 1-2 in preparation.

8, the fusion rotein according to claim 4 treats and/or prevents the medicine of HPV relative disease or the application in the vaccine in preparation.

9, the fusion rotein according to claim 4 treats and/or prevents the medicine of cervical cancer or the application in the vaccine in preparation.